Imagen de Portada

A new era for alopecia areata: New treatments and improved knowledge of the condition

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Bianca Maria Piraccini
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Journal of the European Academy of Dermatology and Venereology
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

European expert consensus statement on the systemic treatment of alopecia areata
por: L. Rudnicka, et al.
Publicado: (2024)

Ultra‐high frequency ultrasound predicts baricitinib response in alopecia areata: Towards personalized treatment
por: Flavia Manzo Margiotta, et al.
Publicado: (2025)

Diffuse pattern of alopecia areata in children: A multicentre retrospective study with 67 patients
por: Brenda Costa Buzatto, et al.
Publicado: (2024)

SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
por: Ziad Reguiai, et al.
Publicado: (2025)

A ranking of treatment efficacy in alopecia areata is not possible without head‐to‐head studies
por: Lidia Rudnicka, et al.
Publicado: (2024)

Association of Janus kinase inhibitors with reduced depression in alopecia areata
por: Chih‐Yi Ho, et al.
Publicado: (2025)

Etrasimod for alopecia areata: The scenario for a less extensive and moderate form
por: M. Starace
Publicado: (2025)

Ultraviolet‐induced fluorescence dermoscopy in detecting follicular openings in alopecia areata
por: Xiaofan Jin, et al.
Publicado: (2025)

More than cosmetic: A personal perspective on alopecia areata and therapeutic restoration
por: Catherine S. Taghizadeh, et al.
Publicado: (2026)

Stigmatizing attitudes towards facial psoriasis, atopic dermatitis, vitiligo and alopecia areata
por: Eleonora De Luca, et al.
Publicado: (2025)

Real‐world efficacy and safety of ritlecitinib in alopecia areata: A single‐centre experience
por: Youyu Sheng, et al.
Publicado: (2025)

Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
por: A. Mourtada, et al.
Publicado: (2025)

Real‐life effectiveness and safety of baricitinib in patients with severe alopecia areata: A 24‐week Italian study
por: B. M. Piraccini, et al.
Publicado: (2024)

Baricitinib and low‐dose prednisone for very severe alopecia areata: A retrospective case series
por: Karen Aouar, et al.
Publicado: (2026)

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study
por: B. King, et al.
Publicado: (2025)

Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
por: David Saceda‐Corralo, et al.
Publicado: (2025)

Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia
por: Azael Freites‐Martinez, et al.
Publicado: (2025)

Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
por: Husein Husein‐ElAhmed, et al.
Publicado: (2024)

Methodological concerns in ‘dutasteride in the treatment of frontal fibrosing alopecia’
por: Ana Paula Pedroso Junges, et al.
Publicado: (2025)

Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
por: M. Senna, et al.
Publicado: (2024)

Clinical and histopathological features of alopecia associated with enfortumab vedotin treatment
por: Kazumasa Oya, et al.
Publicado: (2025)

When onychoscopy makes the difference in a longitudinal furrow on the nail plate: Myxoid pseudocyst versus ungual fibrokeratoma
por: Michela Starace, et al.
Publicado: (2024)

Dutasteride in the treatment of frontal fibrosing alopecia: Systematic review and meta‐analysis
por: Hyun‐Min Seo, et al.
Publicado: (2024)

Oral dutasteride is a first‐line treatment for frontal fibrosing alopecia
por: Sergio Vano‐Galvan, et al.
Publicado: (2024)

Alopecia areata: Time for position statement to include new systemic therapeutic advances
por: Julien Seneschal
Publicado: (2024)

Napkin psoriasis and the risk of later psoriasis development: A single‐centre retrospective study
por: Iria Neri, et al.
Publicado: (2024)

Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
por: C. Tziotzios, et al.
Publicado: (2025)

Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
Publicado: (2025)

Lichen planopilaris and frontal fibrosing alopecia‐associated conditions: A retrospective study with 241 patients
por: G. G. Carrascoza, et al.
Publicado: (2024)

Alopecia areata and ritlecitinib: Unravelling response trajectories
por: Julien Seneschal
Publicado: (2025)

Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
por: Nekma Meah, et al.
Publicado: (2025)

Trichoscopy as a monitoring tool in assessing treatment response in scalp pemphigus
por: M. Starace, et al.
Publicado: (2024)

Severity of hair loss and quality of life for patients with central centrifugal cicatricial alopecia
por: M. Agner, et al.
Publicado: (2024)

Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
por: Chaofan Wang, et al.
Publicado: (2025)

Mogamulizumab‐induced alopecia. Multicentric case series: Clinical, trichoscopic and histological characterization
por: Raquel Cavestany Rodríguez, et al.
Publicado: (2025)

Oral dutasteride can be considered a first‐line treatment for frontal fibrosing alopecia until high‐quality clinical trials could show better results with other therapies
por: S. Vano‐Galvan, et al.
Publicado: (2025)

Patch test positive results in patients with biopsy‐proven central centrifugal cicatricial alopecia
por: Rami H. Mahmoud, et al.
Publicado: (2024)

Digital dermoscopy follow‐up for acquired longitudinal melanonychia
por: Elvira Moscarella, et al.
Publicado: (2025)

Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients
por: Matilde Iorizzo, et al.
Publicado: (2025)

Topical corticosteroids in the era of new topical therapies: Balancing efficacy and safety for long‐term use
por: Alexander Egeberg, et al.
Publicado: (2024)